Literature DB >> 32179443

Histological subtypes in triple negative breast cancer are associated with specific information on survival.

Maschenka C A Balkenhol1, Willem Vreuls2, Carla A P Wauters2, Suzanne J J Mol3, Jeroen A W M van der Laak4, Peter Bult5.   

Abstract

Much research has focused on finding novel prognostic biomarkers for triple negative breast cancer (TNBC), whereas only scattered information about the relation between histopathological features and survival in TNBC is available. This study aims to explore the prognostic value of histological subtypes in TNBC. A multicenter retrospective TNBC cohort was established from five Dutch hospitals. All non-neoadjuvantly treated, stage I-III patients with estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 negative breast cancer diagnosed between 2006 and 2014 were included. Clinical and follow-up data (overall survival; OS, relapse free survival; RFS) were retrieved and a central histopathological review was performed. Of 597 patients included (median follow up 62.8 months, median age at diagnosis 56.0 years), 19.4% developed a recurrence. The most prevalent histological subtypes were carcinoma of no special type (NST) (88.4%), metaplastic carcinoma (4.4%) and lobular carcinoma (3.4%). Collectively, tumors of special type were associated with a worse RFS and OS compared to carcinoma NST (RFS HR 1.89; 95% CI 1.18-3.03; p = 0.008; OS HR 1.94; 95% CI 1.28-2.92; p = 0.002). Substantial differences in survival, however, were present between the different histological subtypes. In the presented TNBC cohort, special histological subtype was in general associated with less favorable survival. However, within the group of tumors of special type there were differences in survival between the different subtypes. Accurate histological examination can provide specific prognostic information that may potentially enable more personalized treatment and surveillance regimes for TNBC patients.
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Histological subtypes; Histology; Prognosis; Survival; Triple negative breast cancer

Mesh:

Year:  2020        PMID: 32179443     DOI: 10.1016/j.anndiagpath.2020.151490

Source DB:  PubMed          Journal:  Ann Diagn Pathol        ISSN: 1092-9134            Impact factor:   2.090


  9 in total

Review 1.  Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features.

Authors:  Sergey Vtorushin; Anastasia Dulesova; Nadezhda Krakhmal
Journal:  J Zhejiang Univ Sci B       Date:  2022-08-15       Impact factor: 5.552

Review 2.  Triple-negative breast cancer: A run-through of features, classification and current therapies.

Authors:  Meghana Manjunath; Bibha Choudhary
Journal:  Oncol Lett       Date:  2021-05-05       Impact factor: 2.967

3.  Combined mRNAs and clinical factors model on predicting prognosis in patients with triple-negative breast cancer.

Authors:  Yanjun Hu; Dehong Zou
Journal:  PLoS One       Date:  2021-12-29       Impact factor: 3.240

Review 4.  Precision Breast Cancer Medicine: Early Stage Triple Negative Breast Cancer-A Review of Molecular Characterisation, Therapeutic Targets and Future Trends.

Authors:  Karen Pinilla; Lynsey M Drewett; Rebecca Lucey; Jean E Abraham
Journal:  Front Oncol       Date:  2022-08-08       Impact factor: 5.738

Review 5.  Differences of Clinicopathological Features between Metaplastic Breast Carcinoma and Nonspecific Invasive Breast Carcinoma and Prognostic Profile of Metaplastic Breast Carcinoma.

Authors:  Yue Qiu; Yuhui Chen; Li Zhu; Hongye Chen; Yongjing Dai; Baoshi Bao; Lin Tian; Xiaopeng Hao; Jiandong Wang
Journal:  Breast J       Date:  2022-08-22       Impact factor: 2.269

6.  Nomogram for the prediction of triple-negative breast cancer histological heterogeneity based on multiparameter MRI features: A preliminary study including metaplastic carcinoma and non- metaplastic carcinoma.

Authors:  Qing-Cong Kong; Wen-Jie Tang; Si-Yi Chen; Wen-Ke Hu; Yue Hu; Yun-Shi Liang; Qiong-Qiong Zhang; Zi-Xuan Cheng; Di Huang; Jing Yang; Yuan Guo
Journal:  Front Oncol       Date:  2022-09-20       Impact factor: 5.738

7.  Clinico-pathological relationship between androgen receptor and tumour infiltrating lymphocytes in triple negative breast cancer.

Authors:  Hagar Elghazawy; Joaira Bakkach; Thanaa Helal; Ahmed M Aref; Mohamed Kelany; Lamiaa E Abdallah; Fatma S Abdelbakey; Dalia Ali; Doaa Z Ali; Mai O Ahmed; Amer Ali Abd El-Hafeez; Pradipta Ghosh; Mohamed O Alorabi
Journal:  Ecancermedicalscience       Date:  2021-11-11

8.  A Machine Learning Approach to Differentiate Two Specific Breast Cancer Subtypes Using Androgen Receptor Pathway Genes.

Authors:  Taobo Hu; Guiyang Zhao; Yiqiang Liu; Mengping Long
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

9.  Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study.

Authors:  Serdar Altinay; Laurent Arnould; Maschenka Balkenhol; Glenn Broeckx; Octavio Burguès; Cecile Colpaert; Franceska Dedeurwaerdere; Benjamin Dessauvagie; Valérie Duwel; Giuseppe Floris; Stephen Fox; Clara Gerosa; Delfyne Hastir; Shabnam Jaffer; Eline Kurpershoek; Magali Lacroix-Triki; Andoni Laka; Kathleen Lambein; Gaëtan Marie MacGrogan; Caterina Marchiò; Maria-Dolores Martin Martinez; Sharon Nofech-Mozes; Dieter Peeters; Alberto Ravarino; Emily Reisenbichler; Erika Resetkova; Souzan Sanati; Anne-Marie Schelfhout; Vera Schelfhout; Abeer Shaaban; Renata Sinke; Claudia M Stanciu-Pop; Carolien H M van Deurzen; Koen K Van de Vijver; Anne-Sophie Van Rompuy; Anne Vincent-Salomon; Hannah Y Wen; Serena Wong; Mieke R Van Bockstal; Aline François; Caroline Bouzin; Christine Galant
Journal:  Mod Pathol       Date:  2021-07-03       Impact factor: 7.842

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.